Robert Taub, M.D., at Columbia’s Herbert Irving Comprehensive Cancer Center, takes a special interest in asbestos cancer and is hopeful about future treatment options.
His specialization has led him to constantly strive for improvements in the field of oncology and mesothelioma, and his personal guidance has led to significant improvements at the cancer center.
Taub headed the Mesothelioma Center at Columbia University before the school absorbed the program into its division of hematology and oncology.
Current surgical and chemotherapy treatments of patients with malignant pleural mesothelioma are unsatisfactory (and) have not been shown to significantly prolong survival.
Columbia Medical Center now uses techniques such as intracavitary chemotherapy. In this method, which is used to treat peritoneal mesothelioma, periodic doses of chemotherapy are delivered directly into the abdomen. This treatment lasts 12 weeks and begins when cancerous tissue has been surgically removed.
We can help you or a loved one get in contact with Dr. Taub and find the treatment that's best for you.
Taub has served as principal investigator in numerous cancer clinical trials. Since 1999, he has continuously researched the efficacy of multimodal therapy, a method now commonly used in treatment.
Fast Fact: Dr. Taub served as lead investigator in clinical trials coordinated by Columbia’s interdepartmental Center for Lung Failure and the Columbia University Medical Center.
He also began a clinical study in 2008 to evaluate the effectiveness of targeted radiation in treating pleural mesothelioma. The targeted radiation aimed to kill cancer cells on the surface of the lung without damaging nearby vital tissue.
Taub also worked at New York-Presbyterian Hospital. He has authored or co-authored more than 130 peer-reviewed articles.
View our resources for patients and familiesGet Help Today